Royalty Pharma plc
RPRX
Rangering i aksjer
#867
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a... Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Aksjekurs
$62.21
Sist synkronisert: 2026-10-20
Markedsverdi
$27.70B
Endring (1 dag)
3.22%
Endring (1 år)
65.98%
Land
US
Handel Royalty Pharma plc (RPRX)
Kategori
Healthcare
P/S-forhold for Royalty Pharma plc (RPRX)
P/S-forhold per October 2026 TTM: 10.31
Ifølge Royalty Pharma plc sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/S-forhold (TTM) 10.31. Ved slutten av 2023 hadde selskapet et P/S-forhold på 5.34.
P/S-historikk for Royalty Pharma plc fra 2015 til 2026
P/S-forhold ved hvert års slutt
| År | P/S-forhold | Endre |
|---|---|---|
| 2026 (TTM) | 10.31 | 104.99% |
| 2024 | 5.03 | -5.87% |
| 2023 | 5.34 | -30.98% |
| 2022 | 7.74 | 7.16% |
| 2021 | 7.22 | -21.12% |
| 2020 | 9.15 | 5.36% |
| 2019 | 8.69 | -1.07% |
| 2018 | 8.78 | -10.97% |
| 2017 | 9.86 | -31.45% |
| 2016 | 14.39 | -11.98% |
| 2015 | 16.35 | 0.00% |
P/S-forhold for lignende selskaper eller konkurrenter
| Selskap | P/S-forhold | Forskjell i P/S-forhold | Land |
|---|---|---|---|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| 15.12 | 46.67% |
US
|
|
| 2.36 | -77.11% |
HK
|
